A case of immune-associated myocarditis after using sindillizumab with renal cancer and diabetes was reported. By analyzing the association between the myocarditis and sindillizumab, based on the evidence-based evidence, clinical pharmacists provided appropriate treatment plan, and carried out pharmaceutical care for the patient the whole time. The patient received timely treatment for immune-associated myocarditis, and the blood glucose was controlled in a stable range.

1.Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis[J]. Lancet, 2018, 391(10124): 933. DOI: 10.1016/S0140-6736(18)30533-6.

2.Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors[J]. J Am Coll Cardiol, 2018, 71(16): 1755-1764. DOI: 10.1016/j.jacc.2018.02.037.

3.Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity[J]. Circulation, 2017, 136(21): 2085-2087. DOI: 10.1161/CIRCULATIONAHA.117.030571.

4.王汉萍,周佳鑫,郭潇潇,等. 免疫检查点抑制剂相关毒副作用管理之激素的使用[J]. 中国肺癌杂志, 2019, 22(10): 615-620. [Wang HP, Zhou JX, Guo XX, et al. The use of glucocorticoid in the management of adverse effects related to immunocheckpoint inhibitors[J]. Chinese Journal of Lung Cancer, 2019, 22(10): 615-620.] DOI: 10.3779/j.issn.1009-3419.2019.10.02.

5.张慧.糖尿病应用不同糖皮质激素和胰岛素的治疗效果观察[J]. 北方药学, 2019, 16(6): 122-123. [Zhang H. Ther-apeutic effect of different glucocorticoids and insulin in diabetes mellitus[J]. Journal of North Pharma-cy, 2019, 16(6): 122-123.] DOI: 10.3969/j.issn.1672-8351. 2019.06.098.

6.Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology[J]. Circulation, 2019, 140(2):80-91. DOI: 10.1161/CIRCULATIONAHA.118.034497.

7.Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunother-apy-related toxicities, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3): 230-241. DOI: 10.6004/jnccn.2020.0012.

8.Hardy T, Yin M, Chavez JA, et al. Acute fatal myocarditis after a single dose of anti-PD-1 immunother-apy, autopsy findings: a case report[J]. Cardiovasc Pathol, 2020, 46: 107202. DOI: 10.1016/j.carpath.2020.107202.

9.Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer[J]. Neurology, 2018, 91(10): e985-e994. DOI: 10.1212/WNL.0000000000006124.

10.Guha A, Al-Kindi S, Jain P, et al. Association between myocarditis and other immune-related adverse events secondary to immune checkpoint inhibitor use[J]. Int J Cancer, 2020, 147(6): 1753-1754. DOI: 10.1002/ijc. 32960.

11.Anquetil C, Salem JE, Lebrun-Vignes B, et al. Immune checkpoint inhibitor- associated myositis: ex-panding the spectrum of cardiac complications of the immunotherapy revolution[J]. Circulation, 2018, 138(7): 743-745. DOI: 10.1161/CIRCULATIONAHA.118.035898.

12.周慧萍,唐源,陈永春,等. 1例信迪利单抗致免疫性心肌炎引发心力衰竭及呼吸衰竭的病例分析与药学监护[J].中国药师, 2022, 25(6): 1036-1040. [Zhou HP, Tang Y, Chen YC, et al. Case analysis and pharmaceutical care for a case of heart failure and respiratory failure caused by immune-related myocarditis induced by sintili-mab[J]. China Pharmacist, 2022, 25(6): 1036-1040.] DOI: 10.19962/j.cnki.issn1008-049X.2022.06.018.

13.Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reac-tions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. DOI: 10.1038/clpt.1981.154.

14.中国抗癌协会整合肿瘤心脏病学分会，中华医学会心血管病学分会肿瘤心脏病学学组，中国医师协会心血管内科医师分会肿瘤心脏病学专业委员会，等. 免疫检查点抑制剂相关心肌炎监测与管理中国专家共识（2020版）[J]. 中国肿瘤临床, 2020, 47(20): 1027-1038. DOI: 10.3969/j.issn.1000-8179.2020.20.148.

15.中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2020年版）[J].中华糖尿病杂志, 2021, 13(4): 315-409. DOI: 10.3760/cma.j.cn115791-20210221-00095.

16.Liu XX, Zhu XM, Miao Q, et al. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a Meta-analysis[J]. Ann Nutr Metab, 2014, 65(4): 324-32. DOI: 10.1159/000365892.

17.Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with pre-diabetes and type 2 diabetes given thiazolidinediones: a Meta-analysis of randomised clinical trials[J]. Lancet, 2007, 370(9593): 1129-1136. DOI: 10.1016/S0140-6736(07)61514-1.

18.Tanaka K, okada Y, Mori H, et al. The effects of mitiglinide and repaglinide on postprandial hypergly-cemia in patients undergoing methylprednisolone pulse therapy[J]. Intern Med, 2018, 57(1): 65-70. DOI: 10.2169/internalmedicine.9013-17.

19.Uchinuma H, Ichijo M, Harima N, et al. Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin[J]. BMC Endocr Disord, 2020, 20(1): 58. DOI: 10.1186/s12902-020-0542-5.

20.唐浩淳，夏铮铮，左靖，等. 肿瘤患者免疫检查点抑制药用药安全性的回顾性研究[J]. 药物流行病学杂志, 2020, 29(5): 315-318,323. [Tang HC, Xia ZZ, Zuo J, et al. A retrospective study on the safety of immunocheckpoint inhibition in cancer patients[J]. Chinese Journal of Pharmacoepidemiology, 2020, 29(5): 315-318,323.] DOI: 10.19960/j.cnki.issn1005-0698.2020.05.004.